Abstract | BACKGROUND: METHODS: RESULTS: In vitro, BIM23B065 treatment decreased GH release in the culture media and downregulated ERK 1/2 and CREB phosphorylation to 22% and 26%, respectively. In vivo, IGF-1 expression decreased to 50 % after 4 weeks of treatment with BIM23B065 using an osmotic pump implant. Moreover, magnetic resonance imaging results showed that the tumor size decreased significantly following treatment with BIM23B065 for 4 weeks. CONCLUSION: The novel chimeric molecule was effective in decreasing IGF-1 and GH levels and may serve as an effective therapeutic agent for acromegaly.
|
Authors | Jean Kim, Ju Hun Oh, Heather Harlem, Michael D Culler, Cheol Ryong Ku, Eun Jig Lee |
Journal | Endocrinology and metabolism (Seoul, Korea)
(Endocrinol Metab (Seoul))
Vol. 35
Issue 1
Pg. 177-187
(03 2020)
ISSN: 2093-5978 [Electronic] Korea (South) |
PMID | 32207278
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2020 Korean Endocrine Society. |
Chemical References |
- BIM23B065
- Intracellular Signaling Peptides and Proteins
- Receptors, Dopamine
- Receptors, Somatostatin
- aryl hydrocarbon receptor-interacting protein
- Somatostatin
- Dopamine
|
Topics |
- Adenoma
(drug therapy, metabolism, pathology)
- Animals
- Cell Proliferation
- Dopamine
(pharmacology)
- Gene Expression Regulation, Neoplastic
(drug effects)
- Growth Hormone-Secreting Pituitary Adenoma
(drug therapy, metabolism, pathology)
- Intracellular Signaling Peptides and Proteins
(physiology)
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Rats
- Receptors, Dopamine
(chemistry)
- Receptors, Somatostatin
(antagonists & inhibitors)
- Somatostatin
(pharmacology)
- Tumor Cells, Cultured
|